Vidac Pharma Holding PLC: Publishes 2025 Annual Report and Financial Statements

Annual Report and audited financial statements for the year ended 31 December 2025 now available

London (pta012/31.08.2026/08:30 UTC+2)

Vidac Pharma Holding Plc, a clinical-stage biopharmaceutical company developing first-in-class therapies targeting the HK2/VDAC metabolic checkpoint, today announced the publication of its Annual Report and Financial Statements for the year ended 31 December 2025.

The Annual Report provides an overview of Vidac Pharma's activities and developments during 2025, together with the Company's audited financial statements for the year ended 31 December 2025.

The Annual Report and Financial Statements are available on the Company's website at www.vidacpharma.com

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. Vidac Pharma's lead drug candidate, VDA-1102, has demonstrated efficacy against advanced Actinic Keratosis (AK) in Phase 2b studies and showed positive results in Cutaneous T-cell Lymphoma (CTCL) in a Phase 2a trial.

Important information

The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Dusseldorf (Primärmarkt), Hamburg, Stuttgart
Other Stock Exchanges:	XETRA